psychoneuro, Table of Contents psychoneuro 2007; 33(1/02): 46-47DOI: 10.1055/s-2007-965867 Blickpunkt © Georg Thieme Verlag KG Stuttgart · New YorkVon der akuten Psychose bis zur Erhaltungstherapie - Wirksamkeit ist das A und das ORecommend Article Abstract Full Text References Quellen 01 Satellitensymposium "From Acute to Long-term: Effectiveness is a Moving Target" am 18. September 2006 in Paris. 02 Kasper S . Lerman MN . MCQuade RD . Saha A . Carson WH . Ali M . Archibald D . Ingenito G . Marcus R . Pigott T . Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol. 2005; 8(1) 131 03 Potkin SG . Saha AR . Kujawa MJ . Carson WH . Ali M . Stock E . Stringfellow J . Ingenito G . Marder SR . Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2003; 60(7) 681-90 04 Pigott TA . Carson WH . Saha AR . et al . For the aripiprazole study group. Aripiprazol patients with chronic schizophrenie: a placebo-controlled 26-week study. J Clin Psychiatry. 2003; 64 1048-1056 05 Kerwin R . Hanssens L . McQuade R . et al . Effectiveness of aripiprazole versus standard of care treatment in patients with schizophrenia: the schizophrenia trial of aripiprazole (STAR) study. Poster präsentiert auf dem 19th ECNP Congress Paris, 2006. 06 Corey-Lisle PK, Kolotkin R, Crosby R, L'Italien GJ, for the STAR study group. Changes in weight and weight-related quality of life in aripiprazole versus standard-of-care treatment. Poster präsentiert auf dem 14th European Congress of Psychiatry (AEP), 2006.
